Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company
that is reimagining therapeutic delivery, today announced
submission of an Investigational New Drug (IND) application with
the U.S. Food and Drug Administration (FDA). The IND application
supports the next phase of development of BT-600, a drug/device
combination designed to use Biora’s NaviCap™ ingestible drug
delivery device with a proprietary liquid formulation of
tofacitinib, for the treatment of moderate to severe ulcerative
colitis.
“Today’s announcement is an important milestone for Biora
Therapeutics. The IND application leverages clinical device
function study data from four separate studies in both healthy
volunteers and patients with active ulcerative colitis, with more
than 40 study participants receiving over 80 NaviCap devices,” said
Ariella Kelman, MD, Chief Medical Officer of Biora Therapeutics.
“We look forward to initiating our phase 1 study in the US this
year and advancing this technology, which we believe could lead to
better patient outcomes in ulcerative colitis,” continued Dr.
Kelman.
The IND application for BT-600 includes extensive manufacturing,
preclinical, human device function, and toxicology data to support
a first-in-human clinical trial for BT-600. The phase 1 trial of
BT-600 is expected to be a randomized, double-blind,
placebo-controlled study to evaluate safety, pharmacokinetics and
pharmacodynamics, including effects on colon tissue, in healthy
volunteers receiving the NaviCap device filled with a novel liquid
formulation of tofacitinib at 5 mg and 10 mg doses. The NaviCap
device has been designed for targeted delivery directly to the
colon in this application.
The FDA will review the application and determine the
acceptability of the data before Biora begins its first clinical
trial for BT-600. It is possible that the FDA will require
additional information.
About the NaviCap™ Targeted Oral Delivery Platform and
BT-600 Biora's NaviCap targeted oral therapeutics
platform utilizes a novel approach that could improve patient
outcomes by enabling delivery of therapeutics directly to the site
of disease, increasing therapeutic levels in tissue while reducing
systemic uptake. For the 1.8 million patients in the United States
who suffer from inflammatory bowel disease (IBD), existing
therapeutics offer less than ideal efficacy, likely because of the
challenges with safely achieving sufficient drug levels in the
affected tissues. Research has shown that targeted delivery of
therapeutics has the potential to improve patient outcomes in
IBD. The NaviCap platform uses an ingestible
device designed for targeted delivery of therapeutics to improve
treatment of IBD. Once swallowed, Biora’s GItrac™ autolocation
technology enables the device to autonomously identify targeted
locations in the GI tract and release a therapeutic dose of up to
500µl. Biora’s BT-600 program consists of a unique,
liquid formulation of tofacitinib delivered to the colon via the
NaviCap device, for the treatment of ulcerative colitis. Studies in
healthy volunteers have demonstrated accurate localization and
delivery in a fasted state and demonstrated the
device’s ability to function in both fasted and fed states,
making it potentially the first ingestible therapeutic delivery
device that does not require fasting or other food restriction for
use. A device function study in participants with active ulcerative
colitis (UC) also demonstrated successful device performance in
active UC patients. The company submitted an Investigational New
Drug (IND) application to begin a phase 1 study for its BT-600
program in September, 2023.
About Biora TherapeuticsBiora Therapeutics is
reimagining therapeutic delivery. By creating innovative smart
pills designed for targeted drug delivery to the GI tract, and
systemic, needle-free delivery of biotherapeutics, the company is
developing therapies to improve patients’ lives.
Biora is focused on development of two therapeutics platforms:
the NaviCap™ targeted oral delivery platform, which is designed to
improve outcomes for patients with inflammatory bowel disease
through treatment at the site of disease in the gastrointestinal
tract, and the BioJet™ systemic oral delivery platform, which is
designed to replace injection for better management of chronic
diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development and clinical
efforts including phase 1 trial readiness, FDA acceptance, and
trial commencement, are forward-looking statements. In some cases,
you can identify forward-looking statements by terms such as “may,”
“might,” “will,” “objective,” “intend,” “should,” “could,” “can,”
“would,” “expect,” “believe,” “design,” “estimate,” “predict,”
“potential,” “plan,” “target,” or the negative of these terms, and
similar expressions intended to identify forward-looking
statements. These statements reflect our plans, estimates, and
expectations, as of the date of this press release. These
statements involve known and unknown risks, uncertainties and other
factors that could cause our actual results to differ materially
from the forward-looking statements expressed or implied in this
press release. Such risks, uncertainties, and other factors
include, among others, our ability to innovate in the field of
therapeutics, our ability to make future filings and initiate
clinical trials on expected timelines or at all, our ability to
obtain and maintain regulatory approval or clearance of our
products on expected timelines or at all, our plans to research,
develop, and commercialize new products, the unpredictable
relationship between preclinical study results and clinical study
results, our expectations regarding allowed patents or intended
grants to result in issued or granted patents, our expectations
regarding opportunities with current or future pharmaceutical
collaborators, our ability to raise sufficient capital to achieve
our business objectives, and those risks described in “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in our Annual Report on Form
10-K for the year ended December 31, 2022 filed with the SEC and
other subsequent documents, including Quarterly Reports, that we
file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Biora Therapeutics (NASDAQ:BIOR)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024